Cargando…

Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis

Patients with rheumatoid arthritis (RA) are treated with drugs that may impact their immune responses to SARS-CoV-2 vaccines. We describe here the anti-Spike (anti-S) IgG and neutralizing antibody responses induced by the mRNA-1273 SARS-CoV-2 vaccine in a 78-years-old patient with RA, who received a...

Descripción completa

Detalles Bibliográficos
Autores principales: Michiels, Yves, Houhou-Fidouh, Nadhira, Collin, Gilles, Berger, Jérôme, Kohli, Evelyne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402486/
https://www.ncbi.nlm.nih.gov/pubmed/34452007
http://dx.doi.org/10.3390/vaccines9080883
_version_ 1783745801229434880
author Michiels, Yves
Houhou-Fidouh, Nadhira
Collin, Gilles
Berger, Jérôme
Kohli, Evelyne
author_facet Michiels, Yves
Houhou-Fidouh, Nadhira
Collin, Gilles
Berger, Jérôme
Kohli, Evelyne
author_sort Michiels, Yves
collection PubMed
description Patients with rheumatoid arthritis (RA) are treated with drugs that may impact their immune responses to SARS-CoV-2 vaccines. We describe here the anti-Spike (anti-S) IgG and neutralizing antibody responses induced by the mRNA-1273 SARS-CoV-2 vaccine in a 78-years-old patient with RA, who received a low-dose combination therapy of methotrexate and adalimumab, shortly before vaccine administration. Both near-normal and impaired immune responses to vaccines have been reported previously in patients treated with these drugs. Our case report shows that, even at low doses, combined methotrexate-adalimumab therapy can be associated with a weak immune response to the mRNA1273 vaccine in elderly patients.
format Online
Article
Text
id pubmed-8402486
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84024862021-08-29 Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis Michiels, Yves Houhou-Fidouh, Nadhira Collin, Gilles Berger, Jérôme Kohli, Evelyne Vaccines (Basel) Case Report Patients with rheumatoid arthritis (RA) are treated with drugs that may impact their immune responses to SARS-CoV-2 vaccines. We describe here the anti-Spike (anti-S) IgG and neutralizing antibody responses induced by the mRNA-1273 SARS-CoV-2 vaccine in a 78-years-old patient with RA, who received a low-dose combination therapy of methotrexate and adalimumab, shortly before vaccine administration. Both near-normal and impaired immune responses to vaccines have been reported previously in patients treated with these drugs. Our case report shows that, even at low doses, combined methotrexate-adalimumab therapy can be associated with a weak immune response to the mRNA1273 vaccine in elderly patients. MDPI 2021-08-09 /pmc/articles/PMC8402486/ /pubmed/34452007 http://dx.doi.org/10.3390/vaccines9080883 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Michiels, Yves
Houhou-Fidouh, Nadhira
Collin, Gilles
Berger, Jérôme
Kohli, Evelyne
Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis
title Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis
title_full Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis
title_fullStr Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis
title_full_unstemmed Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis
title_short Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis
title_sort impact of low-dose methotrexate–adalimumab combination therapy on the antibody response induced by the mrna-1273 sars-cov-2 vaccine: case of an elderly patient with rheumatoid arthritis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402486/
https://www.ncbi.nlm.nih.gov/pubmed/34452007
http://dx.doi.org/10.3390/vaccines9080883
work_keys_str_mv AT michielsyves impactoflowdosemethotrexateadalimumabcombinationtherapyontheantibodyresponseinducedbythemrna1273sarscov2vaccinecaseofanelderlypatientwithrheumatoidarthritis
AT houhoufidouhnadhira impactoflowdosemethotrexateadalimumabcombinationtherapyontheantibodyresponseinducedbythemrna1273sarscov2vaccinecaseofanelderlypatientwithrheumatoidarthritis
AT collingilles impactoflowdosemethotrexateadalimumabcombinationtherapyontheantibodyresponseinducedbythemrna1273sarscov2vaccinecaseofanelderlypatientwithrheumatoidarthritis
AT bergerjerome impactoflowdosemethotrexateadalimumabcombinationtherapyontheantibodyresponseinducedbythemrna1273sarscov2vaccinecaseofanelderlypatientwithrheumatoidarthritis
AT kohlievelyne impactoflowdosemethotrexateadalimumabcombinationtherapyontheantibodyresponseinducedbythemrna1273sarscov2vaccinecaseofanelderlypatientwithrheumatoidarthritis